Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.48 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | TEK | Q02763 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2313598 | 1.00 | BRAF (0.48) | BRAFEML4ALKSRCLCK | |
| SCHEMBL14717844 | 1.00 | BRAF (0.48) | BRAFEML4ALKSRCLCK | |
| SCHEMBL14716947 | 0.94 | BRAF (0.52) | BRAFEML4ALKSRCLCK | |
| SCHEMBL14717716 | 0.94 | BRAF (0.52) | BRAFEML4ALKSRCLCK | |
| SCHEMBL14716944 | 0.94 | BRAF (0.52) | BRAFEML4ALKSRCLCK | |
| SCHEMBL19057069 | 0.90 | BRAF (0.43) | BRAFEML4ALKSRCLCK | |
| SCHEMBL14108418 | 0.90 | BRAF (0.47) | BRAFSRCABL1 | |
| SCHEMBL14717115 | 0.88 | CSF1R (0.53) | BRAFSRCLCKKDRTEK | |
| SCHEMBL14717114 | 0.88 | CSF1R (0.53) | BRAFSRCLCKKDRTEK | |
| SCHEMBL19073339 | 0.84 | BRAF (0.48) | BRAFSRCABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528925-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO LTD (KR) | 2017-07-05 | — | — | EP | claimed |
| US-8999973-B2 | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases | HANMI SCIENCE CO., LTD (KR) | 2015-04-07 | — | — | US | claimed |
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO., LTD. (KR) | 2013-02-28 | — | — | US | claimed |
| EP-2528925-A2 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | Hanmi Science Co., Ltd. (KR) | 2012-12-05 | — | — | EP | claimed |
| WO-2011093684-A2 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI HOLDINGS CO., LTD. (KR) | 2011-08-04 | — | — | WO | claimed |
| EP-2528925-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO LTD (KR) | 2017-07-05 | — | — | EP | disclosed |
| US-8999973-B2 | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases | HANMI SCIENCE CO., LTD (KR) | 2015-04-07 | — | — | US | disclosed |
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO., LTD. (KR) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | CDK2, TK1, DTYMK | BRAF 60/4885EML4 3607/4885ALK 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.